Study on the effects of vericiguat on serum Gal-3 and Cat S levels in patients with chronic congestive heart failure
维立西呱对慢性充血性心衰患者血清Gal-3、Cat S的影响研究

摘要

目的 探讨对慢性充血性心衰患者采取维立西呱手段的价值分析。方法 研究筛选2024年6月-2025年12月本院就诊的80例慢性充血性心衰患者，随机分成2组，即：对照、观察组，各组包含40例；对照组实施常规治疗，观察组加入维立西呱药物治疗；比较2组血清学指标[半乳凝集素-3（Gal-3）、组织蛋白酶S（Cat S）]、心功能、疗效的差异性。结果 Gal-3、Cat S比较，观察组治疗后的Gal-3、Cat S均低于对照组（P<0.05）。观察组治疗后的左室射血分数高于对照组，其左心室收缩期末内径、左心室舒张期末内径低于对照组（P<0.05）。观察组疗效值领先对照组（P<0.05）。结论 维立西呱可降低慢性充血性心衰患者Gal-3、Cat S水平，改善心功能，提高疗效。

Abstract

Objective To evaluate the therapeutic value of vericiguat in patients with chronic congestive heart failure (CHF).
Methods A total of 80 patients with CHF admitted to our hospital from June 2024 to December 2025 were enrolled and randomly divided into two groups (control group and observation group), each comprising 40 cases. The control group received conventional treatment, while the observation group was additionally treated with vericiguat. Differences in serum markers (galectin-3 [Gal-3], cathepsin S [Cat S]), cardiac function, and clinical efficacy were compared between the two groups.
Results Compared with the control group, both Gal-3 and Cat S levels were significantly lower in the observation group post-treatment (P<0.05). The left ventricular ejection fraction in the observation group was higher, whereas the end-systolic and end-diastolic diameters of the left ventricle were significantly smaller than those in the control group (P<0.05). The clinical efficacy in the observation group was superior to that of the control group (P<0.05).
Conclusion   Vericiguat can reduce Gal-3 and Cat S levels, improve cardiac function, and enhance clinical efficacy in patients with chronic congestive heart failure.